Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex…
Insiders
Transactions
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
| RelevantBeneficialStockOwner object (366) |
$460,621
d
cs
10% Holder
|
02/28/24 |
F
|
2,119 x $6.27 = $13,286.13 |
Footnotes
#1 Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024.
|
||
|
$49,547
d
cs
10% Holder
|
02/27/24 |
A
|
3,800 x $0 = $0 |
Footnotes
#1 Represents common stock issued upon satisfaction of certain performance criteria contained in performance stock units ("PSUs") granted in 2021.
#2 The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of the PSUs and does not represent a discretionary transaction by the Reporting Person.
|
|||
|
$47,958
d
cs
10% Holder
|
02/27/24 |
F
|
1,589 x $6.44 = $10,233.16 |
Footnotes
#1 Represents common stock issued upon satisfaction of certain performance criteria contained in performance stock units ("PSUs") granted in 2021.
#2 The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of the PSUs and does not represent a discretionary transaction by the Reporting Person.
|
|||
|
$45,747
d
cs
10% Holder
|
02/02/24 |
F
|
934 x $5.85 = $5,463.90 |
Footnotes
#1 The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of time-based restricted stock units previously granted and does not represent a discretionary transaction by the Reporting Person.
|
|||
|
$46,681
d
cs
10% Holder
|
01/05/24 |
F
|
735 x $5.13 = $3,770.55 |
Footnotes
#1 The disposition reported on this Form 4 represents shares withheld by the Issuer to cover the tax liability upon the vesting of time-based restricted stock units previously granted and does not represent a discretionary transaction by the Reporting Person.
|
|||
Get PRO Today
With PRO you will unlock 36 more insider transactions for Eagle Pharmaceuticals, Inc.
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Borio Luciana Director
- Cahill Brian Joseph CHIEF FINANCIAL OFFICER
- Edlin Richard A. Director
- Glenning Robert Director
- Graves Michael Interim Executive Chair & PEO
- Krawtschuk Christopher Chief Financial Officer
- Moran Michael Shawn EVP, Chief Commercial Officer
- Ratoff Steven B Director
- Simpson Jennifer K. Director
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Borio Luciana Director
- Cahill Brian Joseph CHIEF FINANCIAL OFFICER
- Edlin Richard A. Director
- Glenning Robert Director
- Graves Michael Interim Executive Chair & PEO
- Krawtschuk Christopher Chief Financial Officer
- Moran Michael Shawn EVP, Chief Commercial Officer
- Ratoff Steven B Director
- Simpson Jennifer K. Director